RHOEN-KLINIKUM AG (RHK.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:RHK - DE0007042301 - Common Stock
12.5 EUR
+0.1 (+0.81%)
Taking everything into account, RHK scores 4 out of 10 in our fundamental rating. RHK was compared to 29 industry peers in the Health Care Providers & Services industry. While RHK has a great health rating, there are worries on its profitability. RHK is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year RHK was profitable.
RHK had a positive operating cash flow in the past year.
RHK had positive earnings in each of the past 5 years.
Each year in the past 5 years RHK had a positive operating cash flow.
1.2 Ratios
The Return On Assets of RHK (2.02%) is worse than 66.67% of its industry peers.
Looking at the Return On Equity, with a value of 2.90%, RHK is doing worse than 77.78% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 2.67%, RHK is doing worse than 77.78% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for RHK is below the industry average of 6.67%.
The last Return On Invested Capital (2.67%) for RHK is above the 3 year average (2.34%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.02% | ||
| ROE | 2.9% | ||
| ROIC | 2.67% |
ROA(3y)2%
ROA(5y)1.56%
ROE(3y)2.83%
ROE(5y)2.2%
ROIC(3y)2.34%
ROIC(5y)2.01%
1.3 Margins
RHK has a Profit Margin of 2.28%. This is in the lower half of the industry: RHK underperforms 66.67% of its industry peers.
RHK's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 2.86%, RHK is doing worse than 70.37% of the companies in the same industry.
In the last couple of years the Operating Margin of RHK has declined.
Looking at the Gross Margin, with a value of 66.81%, RHK is in the better half of the industry, outperforming 77.78% of the companies in the same industry.
RHK's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.86% | ||
| PM (TTM) | 2.28% | ||
| GM | 66.81% |
OM growth 3Y11.39%
OM growth 5Y-7.03%
PM growth 3Y10.42%
PM growth 5Y-3.92%
GM growth 3Y-1.4%
GM growth 5Y-0.67%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), RHK is destroying value.
The number of shares outstanding for RHK remains at a similar level compared to 1 year ago.
The number of shares outstanding for RHK remains at a similar level compared to 5 years ago.
The debt/assets ratio for RHK has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 3.04 indicates that RHK is not in any danger for bankruptcy at the moment.
RHK has a better Altman-Z score (3.04) than 77.78% of its industry peers.
RHK has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.09, RHK belongs to the top of the industry, outperforming 92.59% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.04 |
ROIC/WACC0.42
WACC6.42%
2.3 Liquidity
RHK has a Current Ratio of 2.28. This indicates that RHK is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 2.28, RHK belongs to the best of the industry, outperforming 92.59% of the companies in the same industry.
RHK has a Quick Ratio of 2.19. This indicates that RHK is financially healthy and has no problem in meeting its short term obligations.
RHK has a better Quick ratio (2.19) than 92.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.28 | ||
| Quick Ratio | 2.19 |
3. Growth
3.1 Past
RHK shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -15.41%.
RHK shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 0.03% yearly.
RHK shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.10%.
RHK shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.12% yearly.
EPS 1Y (TTM)-15.41%
EPS 3Y15.28%
EPS 5Y0.03%
EPS Q2Q%3.33%
Revenue 1Y (TTM)9.1%
Revenue growth 3Y4.41%
Revenue growth 5Y4.12%
Sales Q2Q%8.37%
3.2 Future
The Earnings Per Share is expected to grow by 11.89% on average over the next years. This is quite good.
RHK is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.24% yearly.
EPS Next Y4.3%
EPS Next 2Y10.47%
EPS Next 3Y11.09%
EPS Next 5Y11.89%
Revenue Next Year6.74%
Revenue Next 2Y5.36%
Revenue Next 3Y6.5%
Revenue Next 5Y6.24%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 21.93, RHK is valued on the expensive side.
70.37% of the companies in the same industry are cheaper than RHK, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of RHK to the average of the S&P500 Index (26.49), we can say RHK is valued inline with the index average.
The Price/Forward Earnings ratio is 16.36, which indicates a correct valuation of RHK.
RHK's Price/Forward Earnings ratio is in line with the industry average.
The average S&P500 Price/Forward Earnings ratio is at 23.69. RHK is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.93 | ||
| Fwd PE | 16.36 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of RHK indicates a rather cheap valuation: RHK is cheaper than 100.00% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 0.14 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates RHK does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)5.1
PEG (5Y)644.88
EPS Next 2Y10.47%
EPS Next 3Y11.09%
5. Dividend
5.1 Amount
RHK has a yearly dividend return of 0.81%, which is pretty low.
Compared to an average industry Dividend Yield of 2.40, RHK has a dividend in line with its industry peers.
Compared to an average S&P500 Dividend Yield of 2.31, RHK's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.81% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
RHK pays out 17.78% of its income as dividend. This is a sustainable payout ratio.
DP17.78%
EPS Next 2Y10.47%
EPS Next 3Y11.09%
FRA:RHK (12/5/2025, 7:00:00 PM)
12.5
+0.1 (+0.81%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners0.55%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap837.00M
Revenue(TTM)1.69B
Net Income(TTM)37.68M
Analysts74.29
Price Target14.45 (15.6%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.81% |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP17.78%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-4.43%
EPS NY rev (3m)-4.43%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.72%
Revenue NY rev (3m)0.72%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.93 | ||
| Fwd PE | 16.36 | ||
| P/S | 0.51 | ||
| P/FCF | N/A | ||
| P/OCF | 13.57 | ||
| P/B | 0.64 | ||
| P/tB | 0.74 | ||
| EV/EBITDA | 0.14 |
EPS(TTM)0.57
EY4.56%
EPS(NY)0.76
Fwd EY6.11%
FCF(TTM)-0.12
FCFYN/A
OCF(TTM)0.92
OCFY7.37%
SpS24.7
BVpS19.41
TBVpS16.81
PEG (NY)5.1
PEG (5Y)644.88
Graham Number15.78
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.02% | ||
| ROE | 2.9% | ||
| ROCE | 3.25% | ||
| ROIC | 2.67% | ||
| ROICexc | 4.45% | ||
| ROICexgc | 5.55% | ||
| OM | 2.86% | ||
| PM (TTM) | 2.28% | ||
| GM | 66.81% | ||
| FCFM | N/A |
ROA(3y)2%
ROA(5y)1.56%
ROE(3y)2.83%
ROE(5y)2.2%
ROIC(3y)2.34%
ROIC(5y)2.01%
ROICexc(3y)3.1%
ROICexc(5y)2.62%
ROICexgc(3y)3.7%
ROICexgc(5y)3.13%
ROCE(3y)2.85%
ROCE(5y)2.44%
ROICexgc growth 3Y17.7%
ROICexgc growth 5Y-1.56%
ROICexc growth 3Y17.75%
ROICexc growth 5Y-1.75%
OM growth 3Y11.39%
OM growth 5Y-7.03%
PM growth 3Y10.42%
PM growth 5Y-3.92%
GM growth 3Y-1.4%
GM growth 5Y-0.67%
F-Score6
Asset Turnover0.89
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 1.07 | ||
| Cap/Depr | 112.99% | ||
| Cap/Sales | 4.21% | ||
| Interest Coverage | 14.78 | ||
| Cash Conversion | 56.66% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.28 | ||
| Quick Ratio | 2.19 | ||
| Altman-Z | 3.04 |
F-Score6
WACC6.42%
ROIC/WACC0.42
Cap/Depr(3y)97.27%
Cap/Depr(5y)108.32%
Cap/Sales(3y)4.24%
Cap/Sales(5y)5.08%
Profit Quality(3y)86.55%
Profit Quality(5y)290.53%
High Growth Momentum
Growth
EPS 1Y (TTM)-15.41%
EPS 3Y15.28%
EPS 5Y0.03%
EPS Q2Q%3.33%
EPS Next Y4.3%
EPS Next 2Y10.47%
EPS Next 3Y11.09%
EPS Next 5Y11.89%
Revenue 1Y (TTM)9.1%
Revenue growth 3Y4.41%
Revenue growth 5Y4.12%
Sales Q2Q%8.37%
Revenue Next Year6.74%
Revenue Next 2Y5.36%
Revenue Next 3Y6.5%
Revenue Next 5Y6.24%
EBIT growth 1Y2.05%
EBIT growth 3Y16.29%
EBIT growth 5Y-3.2%
EBIT Next Year147.27%
EBIT Next 3Y44.19%
EBIT Next 5Y28.34%
FCF growth 1Y26.17%
FCF growth 3Y42.66%
FCF growth 5YN/A
OCF growth 1Y42.49%
OCF growth 3Y9.38%
OCF growth 5Y21.95%
RHOEN-KLINIKUM AG / RHK.DE FAQ
Can you provide the ChartMill fundamental rating for RHOEN-KLINIKUM AG?
ChartMill assigns a fundamental rating of 4 / 10 to RHK.DE.
What is the valuation status for RHK stock?
ChartMill assigns a valuation rating of 2 / 10 to RHOEN-KLINIKUM AG (RHK.DE). This can be considered as Overvalued.
What is the profitability of RHK stock?
RHOEN-KLINIKUM AG (RHK.DE) has a profitability rating of 3 / 10.
What is the valuation of RHOEN-KLINIKUM AG based on its PE and PB ratios?
The Price/Earnings (PE) ratio for RHOEN-KLINIKUM AG (RHK.DE) is 21.93 and the Price/Book (PB) ratio is 0.64.
Can you provide the expected EPS growth for RHK stock?
The Earnings per Share (EPS) of RHOEN-KLINIKUM AG (RHK.DE) is expected to grow by 4.3% in the next year.